An Open Label Direct-to-Consumer Study Assessing the Impact of Health and Wellness Products on GI Health and Related Health Outcomes

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age21-75
SponsorPepsiCo Global R&D

About this trial

The purpose of this study is to:

1. Understand the participant experience using a health and wellness product and effects of the study product on GLP-1 users and those trying to lose weight 2. Understand how participants may use and accept a health and wellness product 3. Understand the side effects of a health and wellness product 4. Evaluate the quality and effects of a health and wellness product on participant health through self-reported measures (electronic surveys) and biomarker collections.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Adults, at least 21-75 years of age at the time of electronic consent, inclusive of all ethnicities, races, and gender identities.

Assigned sex at birth will determine sex-specific recruitment and surveys (male vs female) employed, when needed

Resides in the United States

Has the opportunity for at least 30% improvement in their primary health outcome

Disqualifiers

Report being pregnant, trying to become pregnant, or breastfeeding

Unable to provide a valid US shipping address and mobile phone number

Reports current enrollment in another clinical trial

Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day)

Trial design

Design model

Single group

Treatments tested in this trial

  • A ready-to-mix beverage containing protein, fiber, and electrolytes

    Dietary supplement

    Subjects will consume the ready-to-mix beverage ad-libitum over the 4-week study period.

Treatment groups

133 Participants
are divided into 1 treatment group
Group A: GLP-1 Users and Non-usersExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

PROMIS Constipation 9A

A patient reported outcome measure designed to assess frequency, severity, impact, and discomfort cause by gastrointestinal constipation symptoms over 7 days. The scale consists of 9 items, scored 1 to 5, with 1 being associated with a better outcome and 5 being associated with a worse outcome.

Time frame
At baseline and weeks 1-4 of the intervention

Secondary outcomes

1

Digestion-associated Quality of Life Questionnaire

A validated tool designed to assess impact of gastrointestinal symptoms on the quality of life of healthy individuals over 7 days. The questionnaire consists of 9 items, scaled from Never to Always, with Never being associated with a better outcome and 1 being associated with a worse outcome.

Time frame
At baseline and weeks 1-4 of the intervention
2

PROMIS Belly Pain 5A

A patient reported outcome measure designed to assess the severity of belly pain experienced by participants over 7 days. The scale consists of 5 items, scored 1 to 5, with 1 being associated with a worse outcome and 5 being associated with a better outcome.

Time frame
At baseline and weeks 1-4 of the intervention
3

Satiety Survey

A 4 question survey, scaled 0 (not at all) to 10 (extremely) designed to assess satiety

Time frame
At baseline and weeks 1-4 of the intervention
4

Self-Reported Weight

lbs

Time frame
At baseline and weeks 1-4 of intervention

Other outcomes

1

Adverse Events

Documented changes in health and symptoms through self-report

Time frame
From enrollment through completion of the study, average 5 weeks.
2

Evaluation of an at-home Tiny Health Stool kit

An evaluation of the gut microbiome using shotgun metagenomic sequencing. Used to support exploratory research objectives by complementing participant-reported GI symptoms and behavioral outcomes with biological measures

Time frame
At baseline and upon completion of the 4 week intervention
3

Ferritin

ng/mL. Dried blood from a finger prick collected using at home kit. Used to support exploratory research objectives by complementing participant-reported GI symptoms and behavioral outcomes with biological measures.

Time frame
At baseline and upon completion of the 4 week intervention
4

Homocysteine

ug/mL. Dried blood from a finger prick collected using at home kit. Used to support exploratory research objectives by complementing participant-reported GI symptoms and behavioral outcomes with biological measures.

Time frame
At baseline and upon completion of the 4 week intervention

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

PepsiCo Global R&D

Lead sponsor

Radicle Science Inc.

Collaborator